Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies

Acalabrutinib, alone or in combination with obinutuzumab, showed favorable progression-free survival and overall survival compared with other frontline therapies for chronic lymphocytic leukemia.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news